Two biotech stocks crash on first trading day of the year
Agile Therapeutics released "positive top-line phase 3 results" on Tuesday, but the market did not buy it. Its shares plummeted 74 percent, trumping the 68 percent drop inflicted upon Inotek Pharmaceuticals earlier in the day.